A recent study has shown that TNF-α derived from the inflammatory microenvironment of the fibrotic liver promotes sorafenib resistance via STAT3 activation and that STAT3 antagonists reverse HCC resistance to sorafenib (Jiang et al., 2021). This evidence concerns the gene TNF and hepatocellular carcinoma.